|
|
Article: CSL Biotherapies announces FDA marketing approval of Afluria(R).
- Article from:
- Business Wire
- Article date:
- September 28, 2007
CopyrightCOPYRIGHT 2007 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
New influenza vaccine available for distribution in time for the 2007/2008 season
Global biopharmaceutical company with strong vaccine heritage affirms commitment to help address critical U.S. public health need
KING OF PRUSSIA, Pa. -- CSL Biotherapies, a subsidiary of one of the world's leading manufacturers of influenza vaccine, announced today that the U.S. Food and Drug Administration (FDA) has approved Afluria([R])(influenza virus vaccine) for active immunization of persons age 18 years and older against influenza disease caused by influenza virus subtypes A and type B present in the vaccine. Today's approval marks the company's first entry into the ...